DrugPatentWatch Database Preview
BOEHRINGER INGELHEIM Company Profile
What is the competitive landscape for BOEHRINGER INGELHEIM, and when can generic versions of BOEHRINGER INGELHEIM drugs launch?
BOEHRINGER INGELHEIM has forty-eight approved drugs.
There are ninety-four US patents protecting BOEHRINGER INGELHEIM drugs. There is one tentative approval on BOEHRINGER INGELHEIM drugs.
There are two thousand three hundred and sixteen patent family members on BOEHRINGER INGELHEIM drugs in sixty-seven countries and one hundred and sixty-seven supplementary protection certificates in fifteen countries.
Summary for BOEHRINGER INGELHEIM
| International Patents: | 2316 |
| US Patents: | 94 |
| Tradenames: | 39 |
| Ingredients: | 29 |
| NDAs: | 48 |
| Patent Litigation for BOEHRINGER INGELHEIM: | See patent lawsuits for BOEHRINGER INGELHEIM |
| PTAB Cases with BOEHRINGER INGELHEIM as petitioner: | See PTAB cases with BOEHRINGER INGELHEIM as petitioner |
Drugs and US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | OFEV | nintedanib esylate | CAPSULE;ORAL | 205832-001 | Oct 15, 2014 | RX | Yes | No | 7,119,093 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | RX | Yes | Yes | 8,883,805 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Boehringer Ingelheim | MIRAPEX ER | pramipexole dihydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022421-005 | Feb 19, 2010 | AB | RX | Yes | No | 8,679,533 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756-001 | May 21, 2015 | RX | Yes | Yes | 7,837,235*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | RX | Yes | Yes | 8,178,541 | ➤ Sign Up | ➤ Sign Up | ||||
| Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | RX | Yes | Yes | 7,078,381 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | SPIRIVA RESPIMAT | tiotropium bromide | SPRAY, METERED;INHALATION | 021936-001 | Sep 24, 2014 | 7,104,470*PED | ➤ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | 6,169,181*PED | ➤ Sign Up |
| Boehringer Ingelheim | SPIRIVA RESPIMAT | tiotropium bromide | SPRAY, METERED;INHALATION | 021936-001 | Sep 24, 2014 | 6,176,242 | ➤ Sign Up |
| Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | 6,303,661 | ➤ Sign Up |
| Boehringer Ingelheim | TWYNSTA | amlodipine besylate; telmisartan | TABLET;ORAL | 022401-004 | Oct 16, 2009 | 5,591,762 | ➤ Sign Up |
| Boehringer Ingelheim | TWYNSTA | amlodipine besylate; telmisartan | TABLET;ORAL | 022401-001 | Oct 16, 2009 | 5,591,762 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-releaseTablets | 2.5 mg/1000 mg 5 mg/1000 mg | ➤ Subscribe | 2018-03-28 |
| ➤ Subscribe | Extended-release Tablets | 2.25 mg and 3.75 mg | ➤ Subscribe | 2011-07-26 |
| ➤ Subscribe | Extended-release Tablets | 400 mg | ➤ Subscribe | 2013-06-21 |
| ➤ Subscribe | Tablets | 10 mg/5 mg and 25 mg/5 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Tablets | 80 mg/12.5 mg and 40 mg/12.5 mg | ➤ Subscribe | 2008-12-31 |
| ➤ Subscribe | Extended-release Capsules | 25 mg and 200 mg | ➤ Subscribe | 2007-02-01 |
| ➤ Subscribe | Tablets | 0.125 mg, 0.5 mg, 1 mg and 1.5 mg | ➤ Subscribe | 2005-06-24 |
| ➤ Subscribe | Capsules | eq. to 110 mg base | ➤ Subscribe | 2015-12-15 |
| ➤ Subscribe | Tablets | 0.75 mg | ➤ Subscribe | 2008-07-31 |
| ➤ Subscribe | Oral Suspension | 7.5 mg/5 mL | ➤ Subscribe | 2009-12-17 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Extended-release Tablets | 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg | ➤ Subscribe | 2010-06-01 |
| ➤ Subscribe | Extended-release Tablets | 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 30 mg and 40 mg | ➤ Subscribe | 2017-07-12 |
| ➤ Subscribe | Tablets | 10 mg and 25 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 40 mg and 80 mg | ➤ Subscribe | 2006-12-26 |
| ➤ Subscribe | Tablets | 80 mg/25 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Capsules | eq. to 75 mg base and 150 mg base | ➤ Subscribe | 2014-10-20 |
| ➤ Subscribe | Tablets | 0.25 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Inhalation Powder Capsules | 18 mcg | ➤ Subscribe | 2018-05-11 |
| ➤ Subscribe | Tablets | 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
International Patents for BOEHRINGER INGELHEIM Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Africa | 200500083 | ➤ Sign Up |
| Norway | 20000466 | ➤ Sign Up |
| Taiwan | I345975 | ➤ Sign Up |
| Peru | 04222002 | ➤ Sign Up |
| Eurasian Patent Organization | 200500715 | ➤ Sign Up |
| Croatia | P20030277 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90007 | Netherlands | ➤ Sign Up | PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211 |
| 2014 | Austria | ➤ Sign Up | PRODUCT NAME: AFATINIB, DEREN TAUTOMERE, DEREN STEREOISOMERE UND DEREN SALZE, PHYSIOLOGISCH VERTRAEGLICHE SALZE MIT ANORGANISCHEN ODER ORGANISCHEN SAEUREN ODER BASEN, BEVORZUGT DEREN MALEATSALZE, VORZUGSWEISE DEREN DIMALEATSALZE; REGISTRATION NO/DATE: EU/1/13/879 20130925 |
| 2005008,C0758327 | Lithuania | ➤ Sign Up | PRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025 |
| C0014 | Belgium | ➤ Sign Up | PRODUCT NAME: TELMISARTAN REGISTRATION NO/DATE: EU/1/98/089/001 / 19981211 |
| 0882 | Netherlands | ➤ Sign Up | PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056/001 20151124 |
| 1345910/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: AFATINIB; REGISTRATION NO/DATE: SWISSMEDIC 63042 17.01.2014 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
